{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Zhang L"],"pubmed_abstract":["Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China that has received approvals from the National Medical Products Administration to treat classical Hodgkin's lymphoma, hepatocellular carcinoma, and squamous and non-squamous NSCLC. In a prospective clinical study we led, neoadjuvant sintilimab has led to major and complete pathologic responses, which are recommended as surrogate endpoints for neoadjuvant immunotherapy; however, its effect remains inconclusive in pulmonary ground glass nodules. Meanwhile, combination plans seem more likely to be satisfyin"],"journal":["Biomarker research"],"pagination":["23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9014583"],"repository":["biostudies-literature"],"pubmed_title":["Sintilimab for the treatment of non-small cell lung cancer."],"pmcid":["PMC9014583"],"pubmed_authors":["He J","Xue Q","Lin W","Gao Y","Tan F","Zhang L","Gao S","Li N"],"additional_accession":[]},"is_claimable":false,"name":"Sintilimab for the treatment of non-small cell lung cancer.","description":"Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China that has received approvals from the National Medical Products Administration to treat classical Hodgkin's lymphoma, hepatocellular carcinoma, and squamous and non-squamous NSCLC. In a prospective clinical study we led, neoadjuvant sintilimab has led to major and complete pathologic responses, which are recommended as surrogate endpoints for neoadjuvant immunotherapy; however, its effect remains inconclusive in pulmonary ground glass nodules. Meanwhile, combination plans seem more likely to be satisfyin","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-04T19:31:49.11Z","creation":"2025-02-19T02:57:40.356Z"},"accession":"S-EPMC9014583","cross_references":{"pubmed":["35436956"],"doi":["10.1186/s40364-022-00363-7"]}}